DOCSLIB.ORG

Neuropathology and Ophthalmic Pathology (1697-1738)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neuropathology and Ophthalmic Pathology (1697-1738) VOLUME 33 | SUPPLEMENT 2 | MARCH 2020 MODERN PATHOLOGY ABSTRACTS NEUROPATHOLOGY AND OPHTHALMIC PATHOLOGY (1697-1738) LOS ANGELES CONVENTION CENTER FEBRUARY 29-MARCH 5, 2020 LOS ANGELES, CALIFORNIA 2020 ABSTRACTS | PLATFORM & POSTER PRESENTATIONS EDUCATION COMMITTEE Jason L. Hornick, Chair William C. Faquin Rhonda K. Yantiss, Chair, Abstract Review Board Yuri Fedoriw and Assignment Committee Karen Fritchie Laura W. Lamps, Chair, CME Subcommittee Lakshmi Priya Kunju Anna Marie Mulligan Steven D. Billings, Interactive Microscopy Subcommittee Rish K. Pai Raja R. Seethala, Short Course Coordinator David Papke, Pathologist-in-Training Ilan Weinreb, Subcommittee for Unique Live Course Offerings Vinita Parkash David B. Kaminsky (Ex-Officio) Carlos Parra-Herran Anil V. Parwani Zubair Baloch Rajiv M. Patel Daniel Brat Deepa T. Patil Ashley M. Cimino-Mathews Lynette M. Sholl James R. Cook Nicholas A. Zoumberos, Pathologist-in-Training Sarah Dry ABSTRACT REVIEW BOARD Benjamin Adam Billie Fyfe-Kirschner Michael Lee Natasha Rekhtman Narasimhan Agaram Giovanna Giannico Cheng-Han Lee Jordan Reynolds Rouba Ali-Fehmi Anthony Gill Madelyn Lew Michael Rivera Ghassan Allo Paula Ginter Zaibo Li Andres Roma Isabel Alvarado-Cabrero Tamara Giorgadze Faqian Li Avi Rosenberg Catalina Amador Purva Gopal Ying Li Esther Rossi Roberto Barrios Anuradha Gopalan Haiyan Liu Peter Sadow Rohit Bhargava Abha Goyal Xiuli Liu Steven Salvatore Jennifer Boland Rondell Graham Yen-Chun Liu Souzan Sanati Alain Borczuk Alejandro Gru Lesley Lomo Anjali Saqi Elena Brachtel Nilesh Gupta Tamara Lotan Jeanne Shen Marilyn Bui Mamta Gupta Anthony Magliocco Jiaqi Shi Eric Burks Gillian Hale Kruti Maniar Gabriel Sica Shelley Caltharp Suntrea Hammer Emily Mason Alexa Siddon Barbara Centeno Malini Harigopal David McClintock Deepika Sirohi Joanna Chan Douglas Hartman Bruce McManus Kalliopi Siziopikou Jennifer Chapman John Higgins David Meredith Sara Szabo Hui Chen Mai Hoang Anne Mills Julie Teruya-Feldstein Beth Clark Mojgan Hosseini Neda Moatamed Khin Thway James Conner Aaron Huber Sara Monaco Rashmi Tondon Alejandro Contreras Peter Illei Atis Muehlenbachs Jose Torrealba Claudiu Cotta Doina Ivan Bita Naini Andrew Turk Jennifer Cotter Wei Jiang Dianna Ng Evi Vakiani Sonika Dahiya Vickie Jo Tony Ng Christopher VandenBussche Farbod Darvishian Kirk Jones Michiya Nishino Paul VanderLaan Jessica Davis Neerja Kambham Scott Owens Olga Weinberg Heather Dawson Chiah Sui Kao Jacqueline Parai Sara Wobker Elizabeth Demicco Dipti Karamchandani Yan Peng Shaofeng Yan Katie Dennis Darcy Kerr Manju Prasad Anjana Yeldandi Anand Dighe Ashraf Khan Peter Pytel Akihiko Yoshida Suzanne Dintzis Francesca Khani Stephen Raab Gloria Young Michelle Downes Rebecca King Joseph Rabban Minghao Zhong Andrew Evans Veronica Klepeis Stanley Radio Yaolin Zhou Michael Feely Gregor Krings Emad Rakha Hongfa Zhu Dennis Firchau Asangi Kumarapeli Preetha Ramalingam Debra Zynger Gregory Fishbein Alvaro Laga Priya Rao Andrew Folpe Steven Lagana Robyn Reed Larissa Furtado Keith Lai Michelle Reid To cite abstracts in this publication, please use the following format: Author A, Author B, Author C, et al. Abstract title (abs#). In “File Title.” Modern Pathology 2020; 33 (suppl 2): page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`%3aC1(6-%D1,G<*E%5:%J10K%5-0%,<1D0,%:(%70*<%51;0%A,1(B%5-0%1(57*(05%,E,50;%*(D%70(D07%*%'7:Y0(%51,,A0% D1*B(:,1,H%Q0,A<5,%*(D%51;0%5:%'1(*<%'7:Y0(%D1*B(:,1,%K070%6:;G*70D%':7%6:(6:7D*(60%K15-%5-0%G70J1:A,%<1B-5%;167:,6:GE%B<*,,%,<1D0% D1*B(:,0,H% :87>'.7A%Q0,A<5,%*(D%51;0%5:%'1(*<%D1*B(:,1,%K070%6:;G*70D%F05K00(%5-0%D1B15*<%1;*B1(B%*(D%<1B-5%;167:,6:GEH%L:(6:7D*(60%':7%5-0%'7:Y0(% 51,,A0%D1*B(:,0,%K*,%"$bST%N#ScOH%Q0*,:(,%':7%D1,6:7D*(60%1(6<AD0D%'*1(5%,5*1(1(B%:7%G*751*<<E%D*;*B0D%B<*,,%,<1D0H%/0*(%51;0%5:%'1(*<% D1*B(:,1,%K*,%=H=%;1(A50,H% \1BA70%!%C%!S#a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bM<0[1(C)!%-*,%F00(%1D0(51'10D%*,%*%G7:C;1B7*5:7E%G*5-K*E%1(%6*7D1*6%G706A7,:7%60<<,%*(D%;0,:5-0<1:;*% 60<<,H%^A7%*1;%K*,%5:%D0507;1(0%0[G70,,1:(%*(D%7:<0%:'%U0;*S]bM<0[1(C)!%G*5-K*E%*;:(B%/4,H% 187(2)A%]0,;:G<*,516%/4,%N])^dO%*(D%6<*,,16%/4,%N]PIO%60<<,%K070%6:;G*70D%1(%J157:H%@-0%1('<A0(60%:'%U0;*S]bM<0[1()!%*651J*51:(%:(% ;1B7*51:(%K*,%*,,0,,0D%A,1(B%U0;*S]%,51;A<*51:(%*(D%G<0[1()!%:J070[G70,,1:(H%)%57*(,<*51:(*<%,5ADE%6:;G*70D%M<0[1()!%57*(,671G5,%*(D% G7:501(%0[G70,,1:(%*;:(B%/4,%,AFB7:AG,%*(D%5:%;05*,5*516%,5*5A,H% :87>'.7A%M<0[1()!%G7:501(%0[G70,,1:(%G*7*<<0<0D%;Q&)%<0J0<,%*(D%F:A(D%U0;*S]%1(%-A;*(%M<0[1()!%G:,151J0%/4,H%W(5070,51(B<E.% 57*(,'0651:(%:'%M2P_W&)!%1(%(0B*51J0%])^d%60<<,%<0D%5:%*%3%':<D%1(670*,0D%;1B7*51:(%A(D07%U0;*S]%,51;A<*51:(%K-1<0%57*(,'0651:(%:'% M2P_W&)!%57A(6*50D%':7;,%;1,,1(B%U0;*%D:;*1(%<0D%5:%5-0%:GG:,150%0''065H%@7*(,671G5:;16%*(*<E,1,%:(%-A;*(%/4%,*;G<0,%D0;:(,57*50D% 5-*5%M<0[1()!%;Q&)%0[G70,,1:(%K*,(e5%,1B(1'16*(5<E%D1''070(5%1(%6<*,,16%6:;G*70D%5:%D0,;:G<*,516%/4,H%W(5070,51(B<E.%M<0[1()!%0[G70,,1:(% K*,%-1B-07%1(%;05*,5*516%G*510(5,%5-*(%1(%/TC/4,H%% ^A7%D*5*%,ABB0,5%*%,G061'16%1(J:<J0;0(5%:'%U0;*S]bM<0[1(C)!%G*5-K*E%1(%/4%60<<,%;1B7*51:(H%W5%1,%G:50(51*<<E%1(J:<J0D%1(%5-0%;:<06A<*7% ,AFB7:AG%=%:'%%/4,H%W5,%G7:;1B7*5:7E%0''065%;*E%G*75161G*50%5:%5-0%;05*,5*516%G7:60,,%:'%5-1,%,AF,05%:'%/4,% \1BA70%!%C%!S#$% \1BA70%3%C%!S#$% % % &/)*'>7(/)7A%@:%,A;%AG.%K0%A(D07,6:70D%*%(0K%7:<0%':7%U0;*S]bM<0[1()!.%G7:;:51(B%/4%60<<%;1B7*51:(%*(D%'A75-07%6:770<*50D%M<0[1()!% 0[G70,,1:(%5:%;05*,5*516%,5*5A,H%)<5:B05-07%5-0,0%D*5*%,-:K0D%5-*5%U0;*S]bM<0[1(C)!%;*E%G7:J1D0%(0K%1(,1B-5,%1(5:%/4%;05*,5*516% G:50(51*<H%@-0%,571+1(B%1(%J157:%F<:6+*D0%:'%60<<%;1B7*51:(%70,A<51(B%'7:;%M<0[1()!%065:D:;*1(%D0<051:(%<05%0(J1,1:(%(0K%'10<D,%:'%70,0*76-%5:% 5*7B05%5-1,%7060G5:7%1(%/4,H% % ! !"##% ! !"##% E1MH!%NOO&PQ%RF?9877(/)%()%E9(4+96%+)-%:8*>998).%J'(/L'+7./4+% 20:(1D*,%)7J*(151,!.%X,1*:CV01%L-0(3.%L*7710%2:A103.%/*,,1;:%]f)GAYY:9.%]:(BR1(B%gA3.%X::1%d0K9.%h*(*%M:75(:K3.%40(-*;% 4*D103.%Q*8A%M1<<*13.%M*57161*%):A(3.%/1<-*(%@0<*5*73.%/16-0<<0%)'+-*;13% !6(,-%./%2.C$%G1,(.'13%=$?(513%6$',$*8%@.+%B'F$3$+8%6B8%:6(,-%./%2.C$%G1,(.'13%=$?(513%6$',$*8%J71*,$8%6B8%;6(,-%./%2.C$8% J71*,$8%6B% 1(7*'/7>987A%20:(1D*,%)7J*(151,>%&:(0?%X,1*:CV01%L-0(>%&:(0?%L*7710%2:A10>%&:(0?%X::1%d0K>%&:(0?%Q*8A%M1<<*1>%&:(0?%/1<-*(%@0<*5*7>% &:(0?%/16-0<<0%)'+-*;1>%&:(0% B+*C29/>)-A%@-0%G7:B7*;;0D%60<<%D0*5-%!%NM]C!O%G*5-K*E%1,%*%7060(5<E%706:B(1Y0D%;06-*(1,;%:'%5A;:7%1;;A(0%0J*,1:(H%W(%5-1,%,5ADE.% G7:B7*;;0D%60<<%D0*5-%<1B*(D%!%NM]C2!O%0[G70,,1:(%K*,%0J*<A*50D%1(%SS%G*510(5,%K15-%D1*B(:,0D%B<1:F<*,5:;*%Ng4/O>%=!%G71;*7E%g4/% *(D%3"%706A770(5%g4/%6*,0,H%V0%*1;0D%5:%0J*<A*50%5-0%G*5507(%:'%0[G70,,1:(%:'%M]C2!%N33L9O%FE%1;;A(:-1,5:6-0;1,57E%*(D%*,,0,,%15,% 70<*51:(,-1G%K15-%5-0%6:;;:(%;:<06A<*7%G7:B(:,516%*(D%G70D1651J0%;*7+07,H% 187(2)A%Q057:,G0651J0%,5ADE%:'%6*,0,%,0(5%':7%X:G0U0R%g<1:;*%'7:;%]060;F07%3T!a%5:%)ABA,5%3T!#H%M]C2!%6<:(0%33L9%*(D%/g/@%
Load more

Recommended publications
  • Central Nervous System Tumors General ~1% of Tumors in Adults, but ~25% of Malignancies in Children (Only 2Nd to Leukemia)
    Last updated: 3/4/2021 Prepared by Kurt Schaberg Central Nervous System Tumors General ~1% of tumors in adults, but ~25% of malignancies in children (only 2nd to leukemia). Significant increase in incidence in primary brain tumors in elderly. Metastases to the brain far outnumber primary CNS tumors→ multiple cerebral tumors. One can develop a very good DDX by just location, age, and imaging. Differential Diagnosis by clinical information: Location Pediatric/Young Adult Older Adult Cerebral/ Ganglioglioma, DNET, PXA, Glioblastoma Multiforme (GBM) Supratentorial Ependymoma, AT/RT Infiltrating Astrocytoma (grades II-III), CNS Embryonal Neoplasms Oligodendroglioma, Metastases, Lymphoma, Infection Cerebellar/ PA, Medulloblastoma, Ependymoma, Metastases, Hemangioblastoma, Infratentorial/ Choroid plexus papilloma, AT/RT Choroid plexus papilloma, Subependymoma Fourth ventricle Brainstem PA, DMG Astrocytoma, Glioblastoma, DMG, Metastases Spinal cord Ependymoma, PA, DMG, MPE, Drop Ependymoma, Astrocytoma, DMG, MPE (filum), (intramedullary) metastases Paraganglioma (filum), Spinal cord Meningioma, Schwannoma, Schwannoma, Meningioma, (extramedullary) Metastases, Melanocytoma/melanoma Melanocytoma/melanoma, MPNST Spinal cord Bone tumor, Meningioma, Abscess, Herniated disk, Lymphoma, Abscess, (extradural) Vascular malformation, Metastases, Extra-axial/Dural/ Leukemia/lymphoma, Ewing Sarcoma, Meningioma, SFT, Metastases, Lymphoma, Leptomeningeal Rhabdomyosarcoma, Disseminated medulloblastoma, DLGNT, Sellar/infundibular Pituitary adenoma, Pituitary adenoma,
    [Show full text]
  • Malignant CNS Solid Tumor Rules
    Malignant CNS and Peripheral Nerves Equivalent Terms and Definitions C470-C479, C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753 (Excludes lymphoma and leukemia M9590 – M9992 and Kaposi sarcoma M9140) Introduction Note 1: This section includes the following primary sites: Peripheral nerves C470-C479; cerebral meninges C700; spinal meninges C701; meninges NOS C709; brain C710-C719; spinal cord C720; cauda equina C721; olfactory nerve C722; optic nerve C723; acoustic nerve C724; cranial nerve NOS C725; overlapping lesion of brain and central nervous system C728; nervous system NOS C729; pituitary gland C751; craniopharyngeal duct C752; pineal gland C753. Note 2: Non-malignant intracranial and CNS tumors have a separate set of rules. Note 3: 2007 MPH Rules and 2018 Solid Tumor Rules are used based on date of diagnosis. • Tumors diagnosed 01/01/2007 through 12/31/2017: Use 2007 MPH Rules • Tumors diagnosed 01/01/2018 and later: Use 2018 Solid Tumor Rules • The original tumor diagnosed before 1/1/2018 and a subsequent tumor diagnosed 1/1/2018 or later in the same primary site: Use the 2018 Solid Tumor Rules. Note 4: There must be a histologic, cytologic, radiographic, or clinical diagnosis of a malignant neoplasm /3. Note 5: Tumors from a number of primary sites metastasize to the brain. Do not use these rules for tumors described as metastases; report metastatic tumors using the rules for that primary site. Note 6: Pilocytic astrocytoma/juvenile pilocytic astrocytoma is reportable in North America as a malignant neoplasm 9421/3. • See the Non-malignant CNS Rules when the primary site is optic nerve and the diagnosis is either optic glioma or pilocytic astrocytoma.
    [Show full text]
  • New Jersey State Cancer Registry List of Reportable Diseases and Conditions Effective Date March 10, 2011; Revised March 2019
    New Jersey State Cancer Registry List of reportable diseases and conditions Effective date March 10, 2011; Revised March 2019 General Rules for Reportability (a) If a diagnosis includes any of the following words, every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report the case to the Department in accordance with the provisions of N.J.A.C. 8:57A. Cancer; Carcinoma; Adenocarcinoma; Carcinoid tumor; Leukemia; Lymphoma; Malignant; and/or Sarcoma (b) Every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report any case having a diagnosis listed at (g) below and which contains any of the following terms in the final diagnosis to the Department in accordance with the provisions of N.J.A.C. 8:57A. Apparent(ly); Appears; Compatible/Compatible with; Consistent with; Favors; Malignant appearing; Most likely; Presumed; Probable; Suspect(ed); Suspicious (for); and/or Typical (of) (c) Basal cell carcinomas and squamous cell carcinomas of the skin are NOT reportable, except when they are diagnosed in the labia, clitoris, vulva, prepuce, penis or scrotum. (d) Carcinoma in situ of the cervix and/or cervical squamous intraepithelial neoplasia III (CIN III) are NOT reportable. (e) Insofar as soft tissue tumors can arise in almost any body site, the primary site of the soft tissue tumor shall also be examined for any questionable neoplasm. NJSCR REPORTABILITY LIST – 2019 1 (f) If any uncertainty regarding the reporting of a particular case exists, the health care facility, physician, dentist, other health care provider or independent clinical laboratory shall contact the Department for guidance at (609) 633‐0500 or view information on the following website http://www.nj.gov/health/ces/njscr.shtml.
    [Show full text]
  • Lesions of the Sellar Region Which May Resemble Macroadenomas Lesiones De La Región Selar Que Pueden Parecerse a Macroadenomas
    www.analesderadiologiamexico.com PERMANYER Anales de Radiología México 2016;15(4):251-259 www.permanyer.com ORIGINAL ARTICLE Lesions of the sellar region which may resemble macroadenomas Lesiones de la región selar que pueden parecerse a macroadenomas Stelios Cedi-Zamudio1, M. Gray-Lugo1, A.E. Vega-Gutiérrez2, V.H. Ramos-Pacheco3, L. Manola-Aguilar4 and G.M. Guerrero-Avendaño5 1Médico Residente del Servicio de Radiología e Imagen; 2Medico Radiólogo especialista en Resonancia Magnética; 3Médico Residente de Curso de Alta Especialidad en el servicio de Resonancia Magnética; 4Médico Residente del Servicio de Neuropatología; 5Medico Radiólogo Intervencionista. Hospital General de México Dr. Eduardo Liceaga, Ciudad de México, México ABSTRACT Correspondence to: Stelios Cedi-Zamudio Médico Residente del Servicio de Radiología e Imagen Hospital General de México Dr. Eduardo Liceaga Ciudad de México, México Received in original form: 22-07-2016 E-mail: [email protected] Accepted in final form: 17-09-2016 1665-2118/©2018 Sociedad Mexicana de Radiologia e Imagen, AC. Publicado por Permanyer México SA de CV. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/). Anales de Radiología México. 2016;15 INTRODUCTION are headache, endocrinological disturbances that can be associated to hypopituitarism, hy- The study of the sellar region has had import- perprolactinemia, hypersecretion of growth ant changes throughout time with the evolu- hormone, pituitary apoplexy, and III, IV, and tion of imaging methods that have growingly VI cranial nerve disorders with optic neurop- improved the resolution of images and have athy leading to diplopia with cavernous sinus displaced diagnostic studies used in the 70s syndrome.1 and 80s last century, such as angiography or pneumoencephalography as the first choice The use of MRI as a standard method pro- methods for diagnosis; computed tomogra- vides more information about disorders in phy and magnetic resonance imaging (MRI) the sellar region.
    [Show full text]
  • What Can the Neuroradiologist Really Say?
    The New World Health Organization Classification of Central Nervous System Tumors: REVIEW ARTICLE What Can the Neuroradiologist Really Say? A.G. Osborn SUMMARY: The WHO Classification of Tumors of the Central Nervous System has become the K.L. Salzman worldwide standard for classifying and grading brain neoplasms. The most recent edition (WHO 2007) introduced a number of significant changes that include both additions and redefinitions or clarifica- M.M. Thurnher tions of existing entities. Eight new neoplasms and 4 new variants were introduced. This article J.H. Rees reviews these entities, summarizing both their histology and imaging appearance. Now with more than M. Castillo 3 years of clinical experience following publication of the newest revision, we also ask, “What can the neuroradiologist really say?” Are there imaging findings that could suggest the preoperative diagnosis of a new tumor entity or variant? ABBREVIATIONS: aCPP ϭ atypical choriod plexus papilloma; CNS ϭ central nervous system; CPP ϭ choriod plexus papilloma; CPCa ϭ choriod plexus carcinoma; DNET ϭ dysembryoplastic neuroep- ithelial tumor; EVNCT ϭ extraventricular neurocytoma; MB ϭ medulloblastoma; MBEN ϭ medul- loblastoma with extensive nodularity; PA ϭ pilocytic astrocytoma; PGNT ϭ papillary glioneuronal tumor; PMA ϭ pilomyxoid astrocytoma; PPTID ϭ pineal parenchymal tumor of intermediate differentiation; PTPRϭ papillary tumor of the pineal region; RGNT ϭ rosette-forming glioneuronal tumor; SCO ϭ spindle cell oncocytoma; T1Cϩϭpost-contrast T1-weighted; T1WI ϭ T1-weighted imaging; T2WI ϭ T2-weighted imaging; WHO ϭ World Health Organization he WHO Classification of Tumors of the Central Nervous mors”) as chordoid glioma and astroblastoma.4 Angiocentric TSystem, now in its fourth edition, is the universal standard gliomas are slowly growing solid hemispheric tumors of chil- 1,2 for classifying and grading brain neoplasms.
    [Show full text]
  • Pituicytoma with Significant Tumor Vascularity Mimicking Pituitary Macroadenoma
    Brain Tumor Res Treat 2017;5(2):110-115 / pISSN 2288-2405 / eISSN 2288-2413 CASE REPORT https://doi.org/10.14791/btrt.2017.5.2.110 Pituicytoma with Significant Tumor Vascularity Mimicking Pituitary Macroadenoma Hyuk Ki Shim1, Seung Heon Cha1, Won Ho Cho1, Sung-Hye Park2 1Department of Neurosurgery, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea 2Department of Pathology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea A 19-year-old man presented with bitemporal hemianopsia and was found to have a large sellar and Received July 23, 2017 suprasellar tumor, resembling a pituitary macroadenoma. Emergency transsphenoidal approach was Revised August 19, 2017 attempted because of rapid visual deterioration with headache. However, the approach was compli- Accepted August 21, 2017 cated and stopped by uncontrolled hemorrhage from the tumor. After conventional cerebral angiogra- Correspondence phy and recognition of an unusual pathology, transcranial approach was achieved to prevent permanent Seung Heon Cha visual loss. The final pathological diagnosis was pituicytoma with epithelioid features. Pituicytoma is a Department of Neurosurgery, rare low-grade tumor (WHO Grade I) of pituicytes involving the sellar and suprasellar region, and origi- Pusan National University nating from special glial cells of the neurohypophysis. Because of the high vascularity, the firm consis- School of Medicine, tency, and invasion to surrounding neurovascular structures, a pituicytoma should be included in the Pusan National University Hospital, differential diagnosis of a mass in the sellar and suprasellar area if the tumor shows high enhancement 179 Gudeok-ro, Seo-gu, Busan 49241, Korea with vascular components.
    [Show full text]
  • Pilomyxoid Astrocytomas: a Short Review
    Brain Tumor Pathology (2019) 36:52–55 https://doi.org/10.1007/s10014-019-00343-0 REVIEW ARTICLE Pilomyxoid astrocytomas: a short review Ibrahim Kulac1,2 · Tarik Tihan2 Received: 23 January 2019 / Accepted: 26 March 2019 / Published online: 3 April 2019 © The Japan Society of Brain Tumor Pathology 2019 Abstract Pilomyxoid astrocytoma is a variant of pilocytic astrocytoma and the clinical, histological and molecular data point to a very close relationship as well as a more aggressive biological behavior for the former. WHO 2016 classifcation does not provide a specifc grade for these neoplasms, but there is sufcient evidence in the literature that pilomyxoid astrocytoma has slightly worse prognosis than typical pilocytic astrocytoma. There is increasing evidence that in addition to the MAPK pathway alterations, pilomyxoid astrocytomas harbor genetic alterations that distinguish them from typical pilocytic astrocytoma Keywords Astrocytoma · BRAF · Pediatric glioma · Pilocytic · Pilomyxoid Introduction diencephalic region, but failed to recognize their histological distinction from typical PA. Although PMA could be seen Pilomyxoid astrocytoma (PMA) has been recognized as a anywhere in the central nervous system, the most common variant of pilocytic astrocytoma (PA), and was originally site is hypothalamic/chiasmatic region [1, 3–5]. The tumors classifed as a WHO grade II neoplasm in the 2007 WHO are less common in the spinal cord and cerebellum, with classifcation scheme. The WHO 2016 classifcation still only a handful of cases reported to date [6, 7]. recognizes PMA as a variant of PA, but a specifc grade has Radiologically, PMAs look very similar to PAs but they not been assigned [1, 2].
    [Show full text]
  • An Exceptional Presentation of Pituicytoma Apoplexy: a Case Report
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Serveur académique lausannois ONCOLOGY LETTERS 16: 643-647, 2018 An exceptional presentation of pituicytoma apoplexy: A case report GIULIA COSSU1, JULIEN DIMITRIOU1, JEAN-PHILIPPE BROULAND2, ROY THOMAS DANIEL1 and MAHMOUD MESSERER1 Departments of 1Neurosurgery and 2Clinical Pathology, University Hospital of Lausanne, 1011 Lausanne, Switzerland Received December 22, 2017; Accepted April 5, 2018 DOI: 10.3892/ol.2018.8625 Abstract. Pituicytomas are a rare form of indolent neoplasms, incidence of pituicytomas, and the average age of presentation which typically present with visual disturbance and hypopitu- is 50 years of age (2). No specific risk factors were identified. itarism. Complete resection by a trans-sphenoidal approach is These neoplasms generally present with headaches, visual the optimal treatment. Only 80 cases have been described thus disturbances and manifestations of hypopituitarism (typically far in the current literature and the present case is the first to sexual dysfunction). The clinical presentation is almost iden- describe the development of pituitary apoplexy in the context tical to other more frequent sellar lesions, therefore correctly of a pituicytoma. A 77-year-old man presented with fatigue diagnosing these lesions can be challenging. Of about 80 cases and clinical signs of hypogonadism and a sellar lesion was described in the literature up until now (3), only one previous diagnosed at cerebral magnetic resonance imaging (MRI). A case reported an abrupt onset of clinical features and this was watch-and-wait management was initially decided and 1 year due to an intraventricular haemorrhage (4). after the initial diagnosis, he presented with a thunderclap On imaging, even if pituicytomas present with suspicious headache with images suggestive of pituitary apoplexy.
    [Show full text]
  • Hypothalamic Endocrine Tumors: an Update
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 28 September 2019 doi:10.20944/preprints201909.0314.v1 Peer-reviewed version available at J. Clin. Med. 2019, 8, 1741; doi:10.3390/jcm8101741 Hypothalamic Endocrine Tumors: An Update Sylvia L. Asa1,2 and Ozgur Mete2,3 1Department of Pathology, Case Western University and University Hospitals, Cleveland, 2Department of Pathology, University Health Network, Toronto and 3Department of Laboratory Medicine and Pathobiology, University of Toronto Running Title: Hypothalamic endocrine tumors Dr. Sylvia L. Asa Department of Pathology University Hospitals Cleveland Medical Center Case Western Reserve University Cleveland, Ohio USA Telephone: 216-983-4701 Facsimile: 216-201-5354 Email: [email protected] 1 © 2019 by the author(s). Distributed under a Creative Commons CC BY license. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 28 September 2019 doi:10.20944/preprints201909.0314.v1 Peer-reviewed version available at J. Clin. Med. 2019, 8, 1741; doi:10.3390/jcm8101741 Abstract The hypothalamus is the site of synthesis and secretion of a number of endocrine peptides that are involved in the regulation of hormonal activity of the pituitary and other endocrine targets. Tumors of the hypothalamus have been recognized to have both structural and functional effects including hormone hypersecretion. The classification of these tumors had advanced over the last few years and biomarkers are now available to classify these tumors and provide accurate structure-function correlations. This review provides an overview of tumors in this region that is critical to metabolic homeostasis with a focus on advances in the diagnosis of gangliocytomas, neurocytomas and pituicytomas that are unique to this region.
    [Show full text]
  • A Spontaneously Occurring Malignant Pituicytoma in a Male Sprague Dawley Rat
    J Toxicol Pathol 2015; 28: 171–176 Case Report A spontaneously occurring malignant pituicytoma in a male sprague dawley rat Takayasu Moroki1*, Tomo Sasaki1**, Katsuhiko Yoshizawa2, and Takaaki Doi1 1 Department of Toxicological Research, Research Laboratories, Maruho Co., Ltd., 93 Awata-cho, Chudoji, Shimogyo-ku, Kyoto, Kyoto 600-8815, Japan 2 Department of Pathology II, Kansai Medical University, 2-5-1 Shin-machi, Hirakata, Osaka 573-1010, Japan Abstract: Pituicytoma is an extremely rare neoplasm derived from pituicytes, which are glial cells in the posterior lobe of the pituitary gland. A malignant pituicytoma was found in the intracranial cavity of a 55-week-old male Sprague-Dawley rat. Macroscopically, the tumor was located on the sphenoid bone and involved the pituitary gland. The tumor was composed of sheets of fusiform cells with spindle- or pleomorphic-shaped nuclei and abundant eosinophilic cytoplasms. The cells were arranged in a whirling or irregular growth pattern. Some tumor cells were bizarre multinucleated giant cells with cytoplasmic eosinophilic hyaline droplets. Many tumor cells were strongly positive for vimentin and glial fibrillary acidic protein, and some cells were positive for ED-1 and S-100. These findings closely resembled those of a giant cell glioblastoma derived from the pituitary gland, suggesting anaplastic pituicytoma. From our re- view of the literature, we believe this is the first report of a spontaneous malignant pituicytoma in a rodent. (DOI: 10.1293/tox.2015- 0012; J Toxicol Pathol 2015; 28: 171–176) Key words: glioblastoma, immunohistochemistry, giant cells, pituicytoma, pituitary gland, rats The incidence of spontaneous intracranial tumors derived from the pituitary gland of an older SD rat that was is very low in rats, with the exception of pituitary neo- suggestive of malignant pituicytoma.
    [Show full text]
  • S40779-021-00332-5.Pdf
    Cheng et al. Military Medical Research (2021) 8:39 https://doi.org/10.1186/s40779-021-00332-5 RESEARCH Open Access Clinical features, radiological profiles, pathological features and surgical outcomes of pituicytomas: a report of 11 cases and a pooled analysis of individual patient data Jian-Hua Cheng1†, Ding Nie1†, Bin Li2, Song-Bai Gui1, Chu-Zhong Li2, Ya-Zhuo Zhang2, Luigi Maria Cavallo3 and Peng Zhao1* Abstract Background: Pituicytoma is an extremely rare low-grade glial tumor that is closely related to the neurohypophysis axis. Most studies of pituicytomas include only several cases. To better understand this disease, we reviewed a series of cases of pituicytomas. The diagnosis and treatment of pituicytoma must be further elucidated. Methods: Eleven patients with pituicytoma admitted to Beijing Tiantan Hospital from 2012 to 2019 were selected. The clinical features, including radiological and histological examination, surgical records and prognosis were reviewed. Sixty-eight other previously published cases of pituicytoma also were used to analyze the predictive factors for the results. The Cox regression model was used for univariate and multivariate analyses. Results: Our patients included 5 males (45.5%) and 6 females (54.5%), with a mean age of 49.3 years. The tumor was located in the suprasellar region in 5 patients (45.5%), intrasellar region in 4 patients (36.4%), and intrasellar- suprasellar region in 2 patients (18.2%). All patients were misdiagnosed with other common tumors in the sellar region before the operation. During the operation, gross total resection (GTR) of the tumor was achieved in 6 patients (54.5%), and subtotal resection (STR) was achieved in 5 patients (45.5%).
    [Show full text]
  • January 2020
    Fred Hutch Cancer Surveillance System January, 2020 REGISTRAR PIP Visit SEER*Educate: A comprehensive training platform for registry professionals Clinical Grade for CNS Primaries Using the WHO Grading System for Selected Tumors of the CNS Mary Trimble, CTR If we have a diagnostic biopsy of a tumor, we can code the clinical grade regardless of the primary site. What is odd about Central Nervous System (CNS) tumors (Figures 1 and 2) is that we can code a clinical grade in the absence of a diagnostic biopsy or histologic confirmation for these primaries. For any other primary, we must have histologic or cytologic confirmation in order to code grade at all. So, what makes the Central Nervous System different? How is it we are able to code clinical grade without any histologic confirmation of the tumor? The World Health Organization (WHO) Classification of Tumors of the Central Nervous System, 4th Edition, released in 2016, provides the WHO grading system of CNS tumors as a uniform way to categorize CNS tumors. Figure 1 Figure 2 Lobes of the Cerebellum Pituitary and Pineal Glands American Joint CommiAee on Cancer (AJCC) Manual, 8th EdiFon - Table 72.2 This four-tiered grade scale helps to classify select CNS histologies based on proliferative potential and the risk of spread or recurrence. In other words, the WHO grade is a malignancy scale where the higher the WHO grade, the more aggressive the clinical course expected for the tumor.” This WHO classification can be seen as part of a larger clinical definition for select histologies and can therefore be used to assign grade without histologic confirmation.
    [Show full text]